Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
about
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
P2860
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Baseline characteristics and i ...... real-world clinical practice.
@ast
Baseline characteristics and i ...... real-world clinical practice.
@en
type
label
Baseline characteristics and i ...... real-world clinical practice.
@ast
Baseline characteristics and i ...... real-world clinical practice.
@en
prefLabel
Baseline characteristics and i ...... real-world clinical practice.
@ast
Baseline characteristics and i ...... real-world clinical practice.
@en
P2093
P2860
P1476
Baseline characteristics and i ...... real-world clinical practice.
@en
P2093
Hiromi Tabuchi
Hiroshi Maegawa
Ichiro Nakamura
Kazuyuki Tobe
P2860
P304
P356
10.1080/14656566.2016.1217994
P407
P577
2016-07-27T00:00:00Z